BDBM528133 1-{[2-(3,3-difluoropyrrolidin-1-yl)pyrimidin-5-yl]methyl}-N-{[5-methoxy-2-(1,2,3,4- tetrazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide::US11180484, Example 88

SMILES COCc1nn(Cc2cnc(nc2)N2CCC(F)(F)C2)cc1C(=O)NCc1cc(OC)ccc1-n1cnnn1

InChI Key InChIKey=GXMGYLDFFLDKJK-UHFFFAOYSA-N

Data  1 KI  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 528133   

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528133(1-{[2-(3,3-difluoropyrrolidin-1-yl)pyrimidin-5-yl]...)
Affinity DataIC50: 8.30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528133(1-{[2-(3,3-difluoropyrrolidin-1-yl)pyrimidin-5-yl]...)
Affinity DataIC50: 4.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528133(1-{[2-(3,3-difluoropyrrolidin-1-yl)pyrimidin-5-yl]...)
Affinity DataIC50: 4.88E+3nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528133(1-{[2-(3,3-difluoropyrrolidin-1-yl)pyrimidin-5-yl]...)
Affinity DataIC50: 4.00E+4nMAssay Description:Factor XIIa inhibitory activity in vitro was determined using standard published methods (see e.g. Shori et al., Biochem. Pharmacol., 1992, 43, 1209;...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528133(1-{[2-(3,3-difluoropyrrolidin-1-yl)pyrimidin-5-yl]...)
Affinity DataKi:  2.90nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent